172 related articles for article (PubMed ID: 37737674)
1. A Study of Dietary Patterns Derived by Cluster Analysis and Their Association With Metabolic Dysfunction-Associated Steatotic Liver Disease Severity Among Hispanic Patients.
Zhang X; Daniel CR; Soltero V; Vargas X; Jain S; Kanwal F; Thrift AP; Balakrishnan M
Am J Gastroenterol; 2024 Mar; 119(3):505-511. PubMed ID: 37737674
[TBL] [Abstract][Full Text] [Related]
2. Association between dairy-rich dietary pattern and metabolic dysfunction-associated steatotic liver disease: Findings from the Korean Genome and Epidemiology Study.
Lee JH; Lee HS; Jeon S; Lee JH; Kwon YJ
Dig Liver Dis; 2024 Feb; ():. PubMed ID: 38336494
[TBL] [Abstract][Full Text] [Related]
3. The impact of metabolic syndrome severity on racial and ethnic disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Elsaid MI; Bridges JFP; Mumtaz K; Li N; Sobotka L; Rustgi VK; Paskett ED
PLoS One; 2024; 19(3):e0299836. PubMed ID: 38489287
[TBL] [Abstract][Full Text] [Related]
4. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.
Ochoa-Allemant P; Marrero JA; Serper M
Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38051551
[TBL] [Abstract][Full Text] [Related]
5. Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study.
Valenzuela-Vallejo L; Chrysafi P; Kouvari M; Guatibonza-Garcia V; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; Mingrone G; George J; Mantzoros CS
Metabolism; 2023 Nov; 148():155694. PubMed ID: 37757973
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in south Central Uganda: A cross-sectional survey.
Enriquez R; Homsi M; Ssekubugu R; Nabukalu D; Zeebari Z; Marrone G; Gigante B; Chang LW; Reynolds SJ; Nalugoda F; Ekström AM; Hagström H; Nordenstedt H
Aliment Pharmacol Ther; 2024 May; 59(9):1111-1121. PubMed ID: 38459720
[TBL] [Abstract][Full Text] [Related]
7. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. Dietary characteristics associated with the risk of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease in non-obese Japanese participants: A cross-sectional study.
Taniguchi H; Ueda M; Sano F; Kobayashi Y; Shima T
JGH Open; 2024 May; 8(5):e13082. PubMed ID: 38779132
[TBL] [Abstract][Full Text] [Related]
10. Association between food insecurity and metabolic dysfunction-associated steatotic liver disease/significant fibrosis measured by fibroscan.
Kim D; Perumpail BJ; Cholankeril G; Ahmed A
Eur J Nutr; 2024 Apr; 63(3):995-1001. PubMed ID: 38260997
[TBL] [Abstract][Full Text] [Related]
11. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
[TBL] [Abstract][Full Text] [Related]
12. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
[TBL] [Abstract][Full Text] [Related]
13. Exploring the landscape of steatotic liver disease in the general US population.
Ciardullo S; Carbone M; Invernizzi P; Perseghin G
Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
[TBL] [Abstract][Full Text] [Related]
14. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
Burmeister Y; Weyer K; Dörre A; Seilheimer B
Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
[TBL] [Abstract][Full Text] [Related]
15. MASLD, hepatic steatosis and fibrosis are associated with the prevalence of chronic kidney disease and retinopathy in adults with type 1 diabetes mellitus.
Mantovani A; Morieri ML; Aldigeri R; Palmisano L; Masulli M; Bonomo K; Baroni MG; Cossu E; Cimini FA; Cavallo G; Buzzetti R; Mignogna C; Leonetti F; Bacci S; Trevisan R; Pollis RM; Cas AD; de Kreutzenberg SV; Targher G
Diabetes Metab; 2024 Jan; 50(1):101497. PubMed ID: 37992857
[TBL] [Abstract][Full Text] [Related]
16. Food insecurity is a risk factor for metabolic dysfunction-associated steatotic liver disease in Latinx children.
Maxwell SL; Price JC; Perito ER; Rosenthal P; Wojcicki JM
Pediatr Obes; 2024 Jun; 19(6):e13109. PubMed ID: 38453472
[TBL] [Abstract][Full Text] [Related]
17. Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease.
Mak AL; Wassenaar N; van Dijk AM; Troelstra M; Houttu V; van Son K; Driessen S; Zwirs D; van den Berg-Faay S; Shumbayawonda E; Runge J; Doukas M; Verheij J; Beuers U; Nieuwdorp M; Cahen DL; Nederveen A; Gurney-Champion O; Holleboom A
JHEP Rep; 2024 Mar; 6(3):100998. PubMed ID: 38379586
[TBL] [Abstract][Full Text] [Related]
18. Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.
Armandi A; Bugianesi E
Eur J Intern Med; 2024 Apr; 122():20-27. PubMed ID: 38262842
[TBL] [Abstract][Full Text] [Related]
19. Exclusive liquor and cocktail consumption is associated with at-risk fibrosis among nonheavy alcohol users with metabolic dysfunction-associated steatotic liver disease.
Ting PS; Lin WT; Huang CK; Lin HY; Tseng TS; Chen PH
Alcohol Clin Exp Res (Hoboken); 2024 Jan; 48(1):88-97. PubMed ID: 38206286
[TBL] [Abstract][Full Text] [Related]
20. Diet quality indices and odds of metabolic dysfunction-associated fatty liver disease: a case-control study.
Ramaiah P; Jamel Baljon K; Alsulami SA; Lindsay GM; Chinnasamy L
Front Nutr; 2023; 10():1251861. PubMed ID: 38260062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
